Navigation Links
Arcturus Therapeutics Announces Collaboration with Takeda Pharmaceuticals to Develop RNA-based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Date:12/6/2016

SAN DIEGO, Dec. 6, 2016 /PRNewswire/ -- Arcturus Therapeutics, Inc. ("Arcturus" or the "Company"), a leading RNA medicines company, announced today that it entered into collaboration with Takeda Pharmaceutical Company Limited, to develop RNA-based therapeutics for the treatment of NASH and other gastrointestinal (GI) related disorders, utilizing Arcturus' wholly-owned therapeutic delivery platform LUNAR™ and UNA Oligomer chemistry. The financial terms were not disclosed.

"Given Takeda's long-standing commitment to and expertise in GI disorders, we are confident we have found an ideal partner to accelerate and maximize the potential of our LUNAR and UNA technology platforms toward the development of novel RNA therapeutics for the treatment of NASH," said Dr. Pad Chivukula, CSO & COO of Arcturus Therapeutics, Inc. "This agreement underscores Arcturus' ability to rapidly discover, design and optimize RNA medicines in areas of unmet need." 

About Arcturus Therapeutics, Inc.   

Founded in 2013 and based in San Diego, Arcturus Therapeutics, Inc. is an RNA medicines company with enabling technologies — UNA Oligomer chemistry and LUNAR™ nanoparticle delivery. Arcturus' versatile RNA therapeutics platform can be applied toward all types of RNA medicines including small interfering RNA, messenger RNA, antisense RNA, microRNA and gene editing therapeutics. The company owns LUNAR™ nanoparticle delivery and unlocked nucleomonomer agent (UNA) technology including UNA Oligomers™, which are covered by its patent portfolio (77 patents and patent applications, issued in the U.S., Europe, Japan and other countries). Arcturus' proprietary UNA technology can be used to target any gene in the human genome, as well as viral genes, and other species for therapeutic purposes. The Company's commitment to the development of novel RNA therapeutics has led to collaborations and license agreements with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and Ultragenyx Pharmaceutical, Inc. For more information, visit www.ArcturusRx.com.

Logo - http://photos.prnewswire.com/prnh/20130531/MM24393LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/arcturus-therapeutics-announces-collaboration-with-takeda-pharmaceuticals-to-develop-rna-based-therapeutics-for-the-treatment-of-nonalcoholic-steatohepatitis-nash-300373830.html


'/>"/>
SOURCE Arcturus Therapeutics
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Arcturus Therapeutics Receives Intent to Grant Notice from the European Patent Office for their Unlocked Nucleomonomer Agent (UNA) Technology
2. Arcturus Therapeutics Announces the Appointment of Drew Weissman M.D., Ph.D. to the Scientific Advisory Board
3. Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines for Defined Indications
4. Arcturus Therapeutics to Present at the Genetic Rx Boston Biotech Conference
5. Arcturus Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
6. Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program
7. Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech
8. Viking Therapeutics Receives Orphan Drug Designation for VK0214 from the U.S. Food and Drug Administration for the Treatment of X-Linked Adrenoleukodystrophy
9. Mission Therapeutics Appoints Colin Goddard as Chairman
10. Research Reports Initiation on Healthcare Stocks -- NuVasive, Smith & Nephew, Nxstage Medical, and Cesca Therapeutics
11. Research Reports Coverage on Biotech Stocks -- Celldex Therapeutics, Amicus Therapeutics, Navidea Biopharma, and Concordia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2017)... 1, 2017 Nutriceutical Holdings (NH), parent company ... (VRS), and KD Pharma Group have decided to join ... KD Pharma Group. KD Pharma Group will become the ... acquire the entire company. "We believe we ... committed to growing the NH companies by providing us ...
(Date:5/26/2017)... 26, 2017  Endo International plc (NASDAQ: ENDP ... CEO, will represent the Company in a fireside chat at ... Tuesday, June 13, 2017 at 10:40 a.m. PT / 1:40 ... in Rancho Palos Verdes, CA. ... will be available on the Company,s website at http://www.endo.com/investors/overview ...
(Date:5/22/2017)... , May 22, 2017  As the specialty ... whole continue to make the revolutionary shift from ... important for ensuring positive patient outcomes and shaping ... are shifting focus away from clinical trials and ... of long-term specialty drug therapy utilization in precise ...
Breaking Medicine Technology:
(Date:6/24/2017)... ... June 24, 2017 , ... Doorknobs are for convenience, deadbolts ... as getting a guard dog or having an alarm system installed. But unless there ... forced entry. Yair Frenkel, owner of TX Premier Locksmith in Killeen, TX says: “In ...
(Date:6/23/2017)... ... June 23, 2017 , ... Yesterday, U.S. Senate Republicans revealed ... repeal and replace the Affordable Care Act (ACA). Like the bill narrowly passed ... Medicaid, a public health insurance program for low-income children, pregnant women, parents of ...
(Date:6/23/2017)... ... 23, 2017 , ... Military Connection friend and veteran advocate Micaela ... Virgin Atlantic lounge. , Bensko is no stranger to the plight of the ... her life to supporting our wounded veterans. A world-class photographer, her riveting photos “The ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ensuring meat products ... videos highlight the importance of correctly using a meat thermometer. The videos feature ... extensive research on consumer food safety habits. Dr. Bruhn explains the variety of ...
(Date:6/23/2017)... ... 23, 2017 , ... PureLife Dental is pleased to announce that California Dental ... As part of the amalgam separator endorsement, all CDA members may purchase an ECO ... the retail value. This partnership between PureLife and CDA is especially timely as it ...
Breaking Medicine News(10 mins):